Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 2;20(13):3265.
doi: 10.3390/ijms20133265.

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease

Valentina Cannone  1   2 , Aderville Cabassi  3 , Riccardo Volpi  3 , John C Burnett  4 ; Jr  4
Affiliations
Review

Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease

Valentina Cannone et al. Int J Mol Sci. .

Abstract

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.

Keywords: atrial natriuretic peptide; cGMP; cardiometabolic disease; guanylyl cyclase receptor A; heart failure; hypertension; metabolic syndrome; natriuretic peptides.; obesity.

PubMed Disclaimer

Conflict of interest statement

Mayo Clinic has licensed MANP to Zumbro Discovery; John C. Burnett Jr. is Co-Founder of Zumbro Discovery and holds equity.

Figures

Figure 1
Figure 1
Atrial natriuretic peptide binds to the guanylyl cyclase A receptor (GC–A) resulting in the production of the second messenger cyclic guanosine monophosphate (cGMP). Protein kinase G (PKG) and cGMP-gated ion channels are then activated and mediate ANP biological actions, which are summarized in the figure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Garbers D.L., Chrisman T.D., Wiegn P., Katafuchi T., Albanesi J.P., Bielinski V., Barylko B., Redfield M.M., Burnett J.C., Jr. Membrane guanylyl cyclase receptors: An update. Trends Endocrinol. Metab. 2006;17:251–258. doi: 10.1016/j.tem.2006.06.006. - DOI - PMC - PubMed
    1. Volpe M., Carnovali M., Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin. Sci. (Lond.) 2016;130:57–77. doi: 10.1042/CS20150469. - DOI - PMC - PubMed
    1. Patel J.B., Valencik M.L., Pritchett A.M., Burnett J.C., Jr., McDonald J.A., Redfield M.M. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am. J. Physiol. Heart Circ. Physiol. 2005;289:H777–H784. doi: 10.1152/ajpheart.00117.2005. - DOI - PubMed
    1. Holtwick R., van Eickels M., Skryabin B.V., Baba H.A., Bubikat A., Begrow F., Schneider M.D., Garbers D.L., Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Investig. 2003;111:1399–1407. doi: 10.1172/JCI17061. - DOI - PMC - PubMed
    1. Calderone A., Thaik C.M., Takahashi N., Chang D.L., Colucci W.S. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Investig. 1998;101:812–818. doi: 10.1172/JCI119883. - DOI - PMC - PubMed

MeSH terms

Substances